The short answer
A bitter orange supplement may add to cardiovascular concerns during methamphetamine treatment, so review the exact extract with your prescriber before use. Human bitter orange findings vary, and the risk from the exact combination has not been measured.
What this answer covers
Citrus aurantium extracts; synephrine content is product-specific. No equivalence to isolated synephrine, ephedrine or ordinary fruit intake.
- Supplement or preparation
- Citrus aurantium
- Medication ingredient
- methamphetamine
One extract raised blood pressure
A small crossover trial of a bitter orange extract standardized to synephrine found higher blood pressure and pulse than placebo for several hours. It did not include methamphetamine.
Another preparation had different results
A short trial of a mixture containing bitter orange, caffeine and green tea found no significant blood-pressure or pulse effect. That does not prove the methamphetamine combination safe, and the mixture cannot isolate bitter orange effects.
Match the product before deciding
Bring the extract strength, synephrine content and other ingredients to your prescriber. Neither trial establishes that eating fruit, using isolated synephrine and taking a concentrated bitter orange blend have the same effect. No protective spacing interval is established.
Symptoms that need attention
Seek urgent medical care for chest pain, shortness of breath or fainting while taking methamphetamine. Tell your prescriber about new palpitations, troublesome stimulation or sleep disruption, and let the treating team decide on medication changes.
Evidence and practical considerations
Side effects & toxicity
Some bitter orange extract data support a blood-pressure precaution; a universal or quantified methamphetamine interaction is not established.
- Exact scope
- Citrus aurantium extracts; synephrine content is product-specific. No equivalence to isolated synephrine, ephedrine or ordinary fruit intake. with Prescribed oral S-methamphetamine hydrochloride; RxNorm 6816 IN and label section 11 establish active-moiety relationship, not dose or stereoisomer interchangeability.
- Medication form and route
- oral
- Timing or duration
- Dose, pattern of use and preparation matter; no universal protective spacing interval established.
What remains uncertain
- Single-product studies and mixtures differ. The imported claim groups bitter orange and synephrine, which must not be treated as equivalent exposures.
Factors that may matter: exact product; other medicines; prescribed dose; baseline cardiovascular or serotonergic risk.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral methamphetamine hydrochloride tablets.
Sections 2.4 and 7.1 identify acidifying agents such as ascorbic acid as lowering levels and alkalinizing agents such as sodium bicarbonate as increasing levels; avoid gastrointestinal and urinary alkalinizing co-use. Sections 5.8 and 7.1 warn about serotonin syndrome with serotonergic agents, specifically including tryptophan and St Johns wort. Section 5.3 calls for blood-pressure and pulse monitoring.
How this applies: RxNorm 6816 IN maps to this SPL, and description confirms active ingredient salt relationship. Applies to prescribed oral S-methamphetamine hydrochloride, not other stimulants or unapproved routes.
Regulatory guidance is not a quantified trial for every named pair. No one-hour supplement spacing instruction. General amphetamine language is explicitly incorporated in this exact methamphetamine product label.
Source 2: original clinical study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 15 healthy young adults.
Blood pressure and heart rate were higher than placebo for several hours.
How this applies: Supports only the specific result and preparation described; applicability to prescribed oral methamphetamine is explicitly limited.
One extract, no methamphetamine. Does not establish identical effects from fruit, every extract or isolated synephrine.
Source 3: original clinical study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 23 mildly overweight adults.
No significant changes in measured heart rate or blood pressure versus placebo.
How this applies: Supports only the specific result and preparation described; applicability to prescribed oral methamphetamine is explicitly limited.
Mixture, limited observation window and no methamphetamine. Cannot attribute the null result to bitter orange alone or establish combination safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current available claims adjudicated from inspected sources; no clinical review asserted. | |
| Research summary published |
Article revision: d1b0436cf5ed1bbb
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.